Scribe Therapeutics Inc. Common Stock (SCTX)

• Market cap: $385M
• 1 day: 7.89%
• 5 days: 26.66%
• 1 month: 9.93%
• 3 months: 9.93%
• 6 months: 9.93%
• Year to date: 9.93%
• 1 year: 9.93%
• 5 years: 9.93%
• 10 years: 9.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.